In total, four experiments were conducted to determine the therapeutic and safety effects of the nutraceutical, turmeric and its active ingredient curcumin on canine and equine. Two studies were conducted on client-owned, moderately arthritic canines, studying the therapeutic and safety effect of curcumin’s anti-inflammatory properties. In Exp. 1, two different dosages, 500 mg, SID of 95% curcumin and 250 mg, BID of 95% liposomal-curcumin, were evaluated in ten moderately arthritic dogs over five months. The dogs in the 95% curcumin group had an overall greater significance in pain reduction by Day 60. Exp. 2, was a follow-up experiment to Exp. 1. In Exp. 2, two different dosages, 500 mg, SID or 100 mg, SID of 95% curcumin, were evaluated in ten moderately arthritic dogs over five months. Findings showed that dogs in the 500 mg, SID group had an overall greater significance in pain reduction by Day 60. Experiment 3 and 4 were a two-part project looking at the anti-microbial and anti-inflammatory properties of turmeric, curcumin, and liposomal-curcumin in cecally-cannulated equine. Exp. 3, was a two-part in vitro study, the first part looked at the anti-microbial effects of turmeric, curcumin, and liposomal-curcumin in reducing opportunistic bacteria found in the equine hindgut, including Streptococcus bovis/equinus complex (SBEC) (P = 0.0056), E. coli K-12 (P = 0.5114), Escherichia coli general (P = 0.1083), Clostridium difficile (P < 0.001), and Clostridium perfringens (P = 0.2439). Treatment D, 95% liposomal-curcumin, numerically reduced the concentration of all five opportunistic strains, and was therefore selected for use in the follow-up in vitro experiment. The second in vitro studied the effects of four different dosages, 15 g, 20 g, 25g, and 30 g of 500 mg/g of 95% liposomal-curcumin at reducing the concentration of SBEC (P < 0.0001), E. coli K-12 (P = 0.0124), E.coli general (P = 0.032), C. difficile (P = 0.5608), and C. perfringens (P = 0.4214). In Exp. 4, 500 mg/g of 95% liposomal-curcumin at 15 g, 25 g, and 35 g, were tested in vivo for anti-inflammatory and anti-microbial therapeutic effects. In total, four experiments were conducted to determine the therapeutic and safety effects of the nutraceutical, turmeric, and its active ingredient curcumin on canines and equines. Two studies were conducted on client-owned, moderately arthritic canines, studying the therapeutic and safety effect of curcumin’s anti-inflammatory properties. In Exp. 1, two different dosages, 500 mg, SID of 95% curcumin and 250 mg, BID of 95% liposomal-curcumin, were evaluated in ten moderately arthritic dogs over five months. The dogs in the 95% curcumin group, overall, had a greater reduction in pain by Day 60. Exp. 2, was a follow-up experiment to Exp. 1. In Exp. 2, two different dosages, 500 mg, SID or 100 mg, SID of 95% curcumin, were evaluated in ten moderately arthritic dogs over five months. We observed that dogs in the 500 mg, SID group had an overall greater significance in pain reduction by Day 60. Experiment 3 and 4 were conducted as a two-part project looking at the antimicrobial and anti-inflammatory properties of turmeric, curcumin, and liposomal-curcumin. The purpose of these studies were to investigate both form and dose of turmeric and its active ingredient, curcumin, on reducing opportunistic bacteria found in the equine hindgut. The bacterial strains of interest included Streptococcus bovis/equinus complex (SBEC), Escherichia coli K-12, Escherichia coli general, Clostridium difficile, and Clostridium perfringens. Exp. 3, was a two-part in vitro study; the first part looked at the antimicrobial effects of turmeric, curcumin, and liposomal-curcumin (LIPC) on reducing opportunistic bacteria found in the equine hindgut, including SBEC (P = 0.006), E. coli K-12 (P = 0.50), E. coli general (P = 0.11), C. difficile (P < 0.0001), and C. perfringens (P = 0.24). The follow-up in vitro 24 h batch culture examined four different dosages (15 g, 20 g, 25 g, and 30 g) of 500 mg/g of LIPC, at reducing the concentration of opportunistic bacteria. These results were utilized to determine the dosing rate in vivo. Exp. 3, in vitro, evaluated the efficacy of antimicrobial and anti-inflammatory properties of LIPC dosed at 15, 20, 25, and 35 g. These results were utilized to determine the dosing rate in vivo. Exp. 4, in vivo, evaluated the efficacy of antimicrobial and anti-inflammatory properties of LIPC dosed at 15, 25, and 35 g compared to a control. In vivo, LIPC’s antimicrobial properties, at 15 g, significantly decreased (P = 0.02) SBEC compared to other treatments. In addition, C. perfringens tended (P = 0.12) to decrease as LIPC dose increased. Non-significant results in digestion, blood parameters, and range of motion suggest there were no adverse side effects from oral dosing increasing doses of curcumin. Valerate decreased (P = 0.005) linearly as LIPC dose increased. As LIPC dose increased, butyrate and iso-valerate decreased (P ≤ 0.03) linearly. However, acetate tended (P = 0.10) to increase linearly as the dose of LIPC increased. Treatment did not affect (P ≥ 0.19) any of the other individual VFAs measured, but increasing doses of LIPC tended (P = 0.10) to increase total VFA concentrations. Additionally, LIPC tended (P = 0.11) to increase total VFA concentrations when compared to control. In the future, further work should be conducted examining liposomal-curcumin’s antimicrobial properties in canine and anti-inflammatory properties in equine over a longer period of time

Twelve working horses were utilized in a completely randomized design to examine the efficacy of curcumin as an anti-parasitic, anti-inflammatory, and anti-microbial. Horses were randomly assigned to either the control (CON) containing no curcumin or to the curcumin (CUR) treatment which was dosed at 15 g of 500 mg/g of 95% curcumin per day (n = 6/treatment). Fecal samples were collected on day 0 before initiation of treatments and then daily for 30 days. Feces from working horses were evaluated for shedding of Streptococcus bovis/ equinus complex, Clostridium difficile, and Clostridium perfringens. Inflammation was observed through erythrocyte sedimentation rate (ESR) via jugular venipuncture every 3-4 days. Horses were fed treatments at 1100 daily and samples were collected prior to administration of treatments. Dosing curcumin at the recommended rate of 15 g per horse had no effect (P ≥ 0.58) on total fecal egg count, strongyles, or ascarids. There was a day effect (P ≤ 0.05) with parasite shedding mimicking the parasites life cycle. Treatment had no effect on ESR (P ≤ 0.42); however, a day effect (P ≤ 0.001) was observed with the CUR horses with ESR decreasing (P = 0.0006) on d 14 and d 21 compared to d 0. There was no treatment (P = 0.34) or day effect (P = 0.53) on concentration of Clostridium perfringens. Similarly, there was no treatment effect for Clostridium difficile (P = 0.51) or SBEC (P = 0.69). Day had an effect (P = 0.0001) on Clostridium difficile, for both CON and CUR horses with all horses having higher concentrations on d 0 and d 1 compared to all other days. Concentrations of SBEC were affected by day (P = 0.05) with concentrations increasing on different days for both CON and CUR horses. Data would suggest that curcumin has a potential benefit as an anti-inflammatory for working horses starting at d 14 when being dosed at 15 g of 500 mg/g of 95% curcumin. This dosage for 30 days however had no additional benefits as an anti-parasitic and anti-microbial. Curcumin has a potentially negative effect on the GIT by increasing opportunistic bacteria and more research is needed to further evaluate the anti-microbial and anti-parasitic effects of curcumin in horses.

CoordenaÃÃo de AperfeÃoamento de Pessoal de NÃvel Superior / Tendo em vista que algumas propriedades terapÃuticas da curcumina jà sÃo bem descritas, dessa forma o presente estudo aponta para um efeito antifÃngico da curcumina frente a cepas de leveduras patogÃnicas resistentes ao fluconazol, cepas de Candida spp. e Cryptococcus neoformans. Todas as cepas estudadas foram inibidas pela curcumina, com diferentes graus de inibiÃÃo entre as espÃcies com CIMs variando entre 8-64 &#956;g/mL. ApÃs a exposiÃÃo das cepas de C. albicans a curcumina, foi observado uma diminuiÃÃo no nÃmero de cÃlulas viÃveis, indicando assim danos Ãs membranas celulares, com possÃvel comprometimento de suas funÃÃes. Os nossos resultados revelaram que apÃs o tratamento com a curcumina, constatamos uma intensificaÃÃo na marcaÃÃo com PI (Iodeto de propÃdio), indicando alteraÃÃes nas membranas celulares. No presente trabalho, a funÃÃo mitocondrial das cÃlulas de C. albicans parece ter sido afetada apÃs exposiÃÃo à curcumina. O colapso no &#916;&#968;m (Potencial Transmembrana Mitocondrial) pode conduzir a aberturas de poros transientes nas membranas mitocondriais. Em relaÃÃo aos diversos mecanismos de aÃÃo descritos para a curcumina, existem evidÃncias de que o DNA à um dos alvos celulares desta molÃcula. Nossos dados sugerem que apÃs a exposiÃÃo à curcumina, as cÃlulas de C. albicans, apresentaram quebras totais nas cadeias de DNA. Em conclusÃo, o composto curcumina apresenta atividade antifÃngica in vitro contra cepas de Candida spp. e Cryptococcus neo-formans resistentes ao fluconazol. AlÃm de promover danos ao DNA e externalizaÃÃo da fosfatidilserina, o respectivo composto parecem atuar em sÃtios especÃficos prÃximos a mitocÃndria das cÃlulas de C. albicans, levando à morte por apoptose. / Considering that some therapeutic properties of curcumin are well described, so the present study points to an antifungal effect of curcumin against strains of pathogenic yeasts resistant to fluconazole, strains of Candida spp. and Cryptococcus neoformans. All strains studied were inhibited by curcumin with different degrees of inhibition among species with MICs ranging from 8-64 mg / ml. After exposure strains of C. albicans, curcumin a decrease in the number of viable cells was observed, thus indicating damage to cell membranes, with possible compromise of their functions. Our results showed that after treatment with curcumin, found in more intense staining with PI (Propidium iodide), indicating changes in cell membranes. In this study, the mitochondrial function of C. albicans cells appears to have been affected after exposure to curcumin. The collapse in &#916;&#968;m (Mitochondrial Transmembrane Potential) can lead to openings of transient pores in the mitochondrial membranes. In relation to the different mechanisms of action described for curcumin, there is evidence that DNA is one of the celular targets of this molecule. Our data suggest that after exposure to curcumin, cells of C. albicans showed total breaks in DNA strands. In conclusion, the compound curcumin has antifungal activity in vitro against strains of Candida spp. and Cryptococcus neoformans resistant to fluconazole. In addition to promoting DNA damage and externalization of phosphatidylserine, the respective compound seem to act at specific sites near mitochondria of C. albicans cells, leading to death by apoptosis.

Curcumina é um composto natural presente na Curcuma longa, que apresenta diversas atividades medicinais, porém sua baixa solubilidade limita sua aplicação médica. Para solucionar esse problema e viabilizar seu uso, diversas pesquisas no campo da nanotecnologia estão sendo feitas. Neste estudo foram obtidas nanopartículas de curcumina utilizando como solventes o etanol (E) e o clorofórmio (C), e através dos procedimentos de agitação magnética e sonicação. As nanopartículas foram caracterizadas por espalhamento de luz dinâmico (DLS), potencial Zeta, microscopia de força atômica (AFM) e pelas espectroscopias no infravermelho (FTIR), no ultravioleta/visível (UV-Vis) e de fluorescência. Foram feitos ensaios de solubilidade, fotodegradação e citotoxicidade. As nanopartículas obtidas com o solvente E e pelos processos de agitação e sonicação foram denominadas de NEA e NES, e com o solvente C de NCA e NCS, respectivamente. Teste inicial de liberação in vitro foi feito para a amostra NCA dispersas em gelatina com posterior recobrimento com Eudragit S100®; esse teste foi feito em HCl (pH 2,0) e tampão fosfato (pH 7,5). A morfologia dessas membranas recobertas ou não com Eudragit S100® foram analisadas por microscopia eletrônica de varredura (MEV). As nanopartículas tiveram um rendimento entre 60 e 78%. O resultado de DLS mostrou a obtenção de partículas nanométricas entre 189 e 248 nm para as NEA, NES e NCS e de 591 nm para NCA, com potencial Zeta acima de |25| mV para todas as amostras. As nanopartículas apresentaram uma fotodegradação mais lenta do que o produto comercial. As espectroscopias de FTIR, UV-Vis e fluorescência apresentaram bandas características da curcumina comercial, indicando que as nanopartículas têm as mesmas características químicas e físicas do bioativo. As nanopartículas mostraram um aumento na solubilidade de 37 a 56 vezes em relação à curcumina comercial. Os ensaios de citotoxicidade indicam que as nanopartículas não apresentaram toxicidade para a linhagem VERO, enquanto que para a linhagem HEp-2 ocasionaram morte celular. Assim, os procedimentos utilizados para o preparo das nanopartículas de curcumina foram eficientes, sendo que uso do solvente E mostrou ser o mais indicado para se obter nanopartículas. A morfologia por MEV das membranas de gelatina/NCA mostra um recobrimento uniforme com Eudragit S100®. Os testes iniciais de liberação in vitro mostraram que as nanopartículas de curcumina são protegidas pelo sistema em pH ácido e liberadas apenas quando em pH 7,5. / Curcumin is a natural compound present in Curcuma longa, which has several medicinal effects but due to its low solubility, its medical application gets constrained. To solve this problem and make it feasible to use, several studies are being made in the nanotechnology field. In this study curcumin nanoparticles were obtained using different solvents, ethanol (E) and chloroform (C), with two procedures, magnetic stirring and sonication. The nanoparticles were characterized by dynamic light scattering (DLS), Zeta potential, atomic force microscopy (AFM) and by infrared spectroscopy (FTIR), ultraviolet/visible spectroscopy (UV-vis), fluorescence spectroscopy. Solubility, photodegradation and cytotoxicity trials were made. The nanoparticles were named NEA and NES when prepared with E solvent, by magnetic stirring and sonication processes, and named NCA and NCS with C solvent, respectively. A preliminary in vitro release test was made with the NCA sample. It was dispersed in gelatin with the Eudragit S100® coating; this release test was done in HCl (pH 2.0) and phosphate buffer (pH 7.5). The membranes with and without Eudragit S100® coating were morphologically analyzed by scanning electron microscopy (SEM). The nanoparticles yield between 60 and 78%. The DLS results showed nanometric particles between 189 and 248 nm for NEA, NES and NCS samples and 591 nm for NCA sample. Moreover, a Zeta potential superior to |25| mV was obtained for all samples. The nanoparticles showed a slower photodegradation compared to the commercial curcumin. The FTIR, UV-vis and fluorescence spectroscopy resulted in characteristic bands, indicating that these nanoparticles have the same chemical and physical characteristics of the commercial curcumin. Likewise, an increase in solubility of 37 to 56 times was observed in comparison with the commercial product. Furthermore, the cytotoxicity assays suggested no toxicity to VERO cell lineage, while death for HEp-2 cell lineage. The procedures used for the curcumin nanoparticles preparation were efficient; however, the most suitable nanoparticles were obtained with E solvent. The morphology by SEM of gelatin/NCA membranes indicates a uniform coating with Eudragit S100®. In vitro release tests showed that curcumin nanoparticles were protected by this system at acid pH and released at pH 7.5.

No description available.

The tumor suppressor protein p53 is one of the major regulators of the cell cycle after DNA damage. In addition to stopping the cycle and repairing DNA, it can, in extreme cases, induce programmed cell death - apoptosis. Mutations in the gene encoding p53 are present in more than 50% of cancer cases. This thesis examines alternative natural polyphenolic substances that could increase the level and expression of p53 protein in tumor cells. These substances could be an alternative to non-specific cytostatics, which bring many undesirable additional effects during treatment. In the theoretical part of the thesis the structure and properties of the p53 protein and describes alternative therapeutic approaches with a focus on polyphenolic substances is explained. The aim of the experimental part was to determine the effect of curcumin and resveratrol in comparison with often used cytostatic drug, doxorubicin, on cell viability of tumor cells and on p53 protein levels. The effect of these substances on the binding of p53 to DNA in yeast systems was also examined. It was found that doxorubin efficiency is many times higher than the examined polyphenolic agents, but resveratrol was showing some potential as a suitable alternative in the treatment of tumors, thanks to the ability to activate apotosis. It was clearly demonstrated that there is an association between induced programmed death and increased p53 protein expression after resveratrol treatment.

This thesis is focused on the study of the effectiveness of active ingredients from natural extracts such as milk thistle and turmeric. The thesis describes the use of modern methods of analysis and identification of active substances located in plants of milk thistle and turmeric. In the experimental part of thesis, which was preceded by a literature search focused on the biological effects of active substances in the chosen natural extracts, the extracts were characterized according to group characteristics (total assessment of polyphenols and flavonoids, assessment of antioxidant activity, and assessment of vitamin C volume and tocopherol). The next part is focused on the study of the encapsulation of natural active substances into the organic particles: liposomes. Silymarin and curcumin were encapsulated as active substances. The idea of a plant with a single active ingredient is usually erroneous. Plants usually contain hundreds of components which cooperate on a given effect. Therefore, the majority of herbalists believe that a simple plant is an active ingredient. However, some plants are known to be containing a particular active phytochemical. For instance, plants such as the milk thistle, turmeric, or a ginkgo are great examples of the plant containing a particular active phytochemical. In these cases, the active compound is disproportionately more effective than the plant itself. Encapsulation efficiency of active ingredients of Silymarin and curcumin was determined by HPLC/PDA. The aim of the analysis was to observe the behavior of elements during the incubation in surrounding of gastric juice model, and the stability while maintaining the particles in model food.

Turmeric extract or active component curcumin may have anti-inflammatory effects in people with chronic inflammatory diseases. The effect of turmeric or curcumin on a wide range of inflammatory markers has not been evaluated in a systematic review. We performed a systematic review of randomized controlled trials (RCTs)evaluating the effects of oral turmeric or curcumin on inflammatory markers (CRP, hsCRP, IL-1, IL-6, TNF)in patients with a wide range of chronic inflammatory diseases. Pubmed, EMBASE, Scopus, the Web of Science, and the Cochrane library were evaluated until June 2018. Random effects meta-analyses with inverse variance methods and stratified by turmeric or curcumin were performed. Effects were expressed as mean differences (MD)and their 95% confidence intervals (CI). Risk of bias of RCTs was evaluated with the Cochrane tool. Nineteen RCTs were identified; included patients had rheumatic diseases, advanced chronic kidney disease with hemodialysis, metabolic syndrome, and cardiovascular diseases. Turmeric was the intervention in 5 RCTs (n = 356)and curcumin/curcuminoids in 14 RCTs (n = 988). Follow up times ranged between 4 and 16 weeks. One RCT had high risk of bias. In comparison to controls, turmeric or curcumin did not significantly decrease levels of CRP (MD -2.71 mg/L, 95%CI -5.73 to 0.31, p = 0.08, 5 studies), hsCRP (MD -1.44 mg/L, 95%CI -2.94 to 0.06, p = 0.06, 6 studies), IL-1 beta (MD -4.25 pg/mL, 95%CI -13.32 to 4.82, p = 0.36, 2 studies), IL-6 (MD -0.71 pg/mL, 95%CI -1.68 to 0.25, p = 0.15), and TNF alpha (MD -1.23 pg/mL, 95%CI -3.01 to 0.55, p = 0.18, 7 studies). There were no differences between turmeric and curcumin interventions. High heterogeneity of effects was observed for all markers across studies, except hsCRP. Other inflammatory markers such as IL-1 alpha, TNF beta, IL-17, and IL-22 had scarce data. Turmeric or curcumin did not decrease several inflammatory markers in patients with chronic inflammatory diseases. / Revisión por pares

Human and non-human primates (NHP) undergo age-related cognitive decline beginning as early as middle-age, even in the absence of an underlying pathology or disease. Growing evidence indicates that an increase in white mater pathology related to rising chronic levels of inflammation may be key contributors to age related cognitive decline. Curcumin (CUR), the active ingredient in turmeric, is a polyphenol nutraceutical with potent anti-inflammatory and antioxidative effects. Several ongoing research studies are underway to explore this potential anti-aging compound. For the first time in a rhesus monkey model of aging, we studied the effects of CUR supplementation on cognition and inflammation. Baseline MRI, blood, CSF and cognitive data were collected for all monkeys. Monkeys were fed daily doses of 500mg of CUR or a vehicle control over 18-months during which three rounds of a battery of cognitive testing was performed along with regular collection of blood, CSF and MRI. Following completion of this testing and specific to this thesis, monkeys were further tested on object discrimination, object and spatial reversal tasks. No significant differences were observed between groups in object discrimination task performance. CUR treatment improved performance on object reversal testing, with treated monkeys making fewer perseverative type errors. At the completion of behavioral testing, serum samples from two-year post treatment onset and brain tissue were harvested for post-mortem analysis of markers of inflammation. The density and morphology of microglia, the resident immune cells of the brain, were examined using immunohistochemistry on serial coronal sections through frontal cortical gray (A46, A25) and while matter (FWM, CC, and CngB) regions that are implicated in cognitive aging. We demonstrated that CUR treatment did not significantly alter the density of presumably immune-activated microglia expressing the MHC class II marker LN3. However, treatment did affect morphological features of microglia specifically within the while matter. Within the white matter, CUR treatment was associated with a significant increase in microglial ramification, evidenced by greater process length, number of nodes and convex-hull area and volume. Increased microglial ramification suggests greater likelihood of microglial surveillance within the white matter associated with CUR treatment. No significant group differences however were observed in the select serum cytokine levels quantified using multiplex ELISA, or in inflammatory gene expression in brain tissue measured with qRT-PCR. While our findings show the benefit of CUR supplementation on cognitive performance and its effects on microglial morphology, further study is needed to understand the precise changes that CUR supplementation may have on inflammation.

Vitamin E TPGS (d-α-tocopheryl polyethylene glycol 1000 succinate), the water-soluble derivative of the naturally occurring d-a-tocopherol, was used initially to overcome malabsorption and correct severe vitamin E deficiency in cholestatic children. The observation that its administration increased the absorption of vitamin D focused attention on its amphiphilic properties as nonionic surfactant and applications in solubilizing lipophilic and poorly soluble compounds and enhancing their absorption and bioavailability. Further research has evaluated its safety and efficacy which combines solubilization and formation of micelle-like particles with inhibition of P-glycoprotein-mediated efflux, the key mechanism to the development of drug resistance. These properties expanded its applications in pharmaceuticals and dietary, disease-specific, supplements for malabsorbing patients. Emerging research on major nutraceuticals and the developing field of cannabinoids have shown that poor water solubility and extensive first-pass metabolism cause poor absorption and bioavailability. This chapter describes the properties, safety, and efficacy of vitamin E TPGS with a focus on its applications in nutraceuticals and cannabinoids.